Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (34)

« Back to Publications

Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial.

Anywaine Z. et al, (2026), The Lancet. Infectious diseases, 26, 302 - 313

Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial

Jenkin D. et al, (2025), The Lancet Microbe, 6, 101022 - 101022

Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK.

Borthwick N. et al, (2025), The Lancet. Microbe, 6

Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial

Conlin K. et al, (2025), Vaccine, 45, 126582 - 126582

Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial

Satti I. et al, (2024), The Lancet Infectious Diseases, 24, 909 - 921

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

Voysey M. et al, (2023), Clinical and Experimental Immunology, 211, 280 - 287

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial

Jenkin D. et al, (2022), The Lancet Microbe, 3, e663 - e671

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment

Folegatti PM. et al, (2022), Vaccine, 40, 5248 - 5262

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

Marchevsky NG. et al, (2022), eBioMedicine, 81, 104128 - 104128

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Ogbe A. et al, (2022), JCI Insight, 7

Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria

Noé A. et al, (2022), Frontiers in Immunology, 13

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040

Load More